Is CYTK or LKFT more profitable?

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to Cytokinetics' net margin of -1,321.12%. Company Net Margins Return on Equity Return on Assets Cytokinetics -1,321.12% N/A -51.01% Lakefront Biotherapeutics American Depositary Shares N/A N/A N/A

Is LKFT or PRAX more profitable?

Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Praxis Precision Medicines' return on equity. Company Net Margins Return on Equity Return on Assets Lakefront Biotherapeutics American Depositary Shares N/A N/A N/A Praxis Precision Medicines N/A -34.15% -32.42%

Is SYRE or LKFT more profitable?

Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Spyre Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Spyre Therapeutics N/A -30.74% -22.23% Lakefront Biotherapeutics American Depositary Shares N/A N/A N/A

Lakefront Biotherapeutics American Depositary Shares (LKFT) Competitors

$29.84 +0.46 (+1.57%)

As of 04:00 PM Eastern

Compare

LKFT vs. CYTK, PRAX, SYRE, IONS, and ALKS

Should you buy Lakefront Biotherapeutics American Depositary Shares stock or one of its competitors? Lakefront Biotherapeutics American Depositary Shares's main competitors and comparable companies include Cytokinetics (CYTK), Praxis Precision Medicines (PRAX), Spyre Therapeutics (SYRE), Ionis Pharmaceuticals (IONS), and Alkermes (ALKS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Lakefront Biotherapeutics American Depositary Shares compare to Cytokinetics?

Cytokinetics (NASDAQ:CYTK) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and dividends.

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to Cytokinetics' net margin of -1,321.12%.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-1,321.12%	N/A	-51.01%
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A

Cytokinetics has a beta of 0.36, indicating that its stock price is 64% less volatile than the broader market. Comparatively, Lakefront Biotherapeutics American Depositary Shares has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market.

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are held by institutional investors. 2.6% of Cytokinetics shares are held by company insiders. Comparatively, 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Lakefront Biotherapeutics American Depositary Shares had 1 more articles in the media than Cytokinetics. MarketBeat recorded 11 mentions for Lakefront Biotherapeutics American Depositary Shares and 10 mentions for Cytokinetics. Lakefront Biotherapeutics American Depositary Shares' average media sentiment score of 1.02 beat Cytokinetics' score of 0.60 indicating that Lakefront Biotherapeutics American Depositary Shares is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Lakefront Biotherapeutics American Depositary Shares	4 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Cytokinetics presently has a consensus target price of $103.37, indicating a potential upside of 56.24%. Lakefront Biotherapeutics American Depositary Shares has a consensus target price of $37.00, indicating a potential upside of 23.99%. Given Cytokinetics' stronger consensus rating and higher probable upside, research analysts plainly believe Cytokinetics is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.85
Lakefront Biotherapeutics American Depositary Shares	0 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.56

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Cytokinetics. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$88.04M	93.51	-$784.96M	-$7.22	N/A
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.56	$363.05M	-$1.41	N/A

Summary

Lakefront Biotherapeutics American Depositary Shares beats Cytokinetics on 10 of the 16 factors compared between the two stocks.

How does Lakefront Biotherapeutics American Depositary Shares compare to Praxis Precision Medicines?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and Praxis Precision Medicines (NASDAQ:PRAX) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings.

Lakefront Biotherapeutics American Depositary Shares currently has a consensus price target of $37.00, suggesting a potential upside of 23.99%. Praxis Precision Medicines has a consensus price target of $612.42, suggesting a potential upside of 114.40%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, analysts plainly believe Praxis Precision Medicines is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	0 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.56
Praxis Precision Medicines	2 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	3 Strong Buy rating(s)	2.95

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.28, suggesting that its share price is 72% less volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.76, suggesting that its share price is 176% more volatile than the broader market.

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are held by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are held by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are held by insiders. Comparatively, 3.0% of Praxis Precision Medicines shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Lakefront Biotherapeutics American Depositary Shares had 7 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 11 mentions for Lakefront Biotherapeutics American Depositary Shares and 4 mentions for Praxis Precision Medicines. Lakefront Biotherapeutics American Depositary Shares' average media sentiment score of 1.02 beat Praxis Precision Medicines' score of 0.62 indicating that Lakefront Biotherapeutics American Depositary Shares is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lakefront Biotherapeutics American Depositary Shares	4 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Praxis Precision Medicines	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Lakefront Biotherapeutics American Depositary Shares, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.56	$363.05M	-$1.41	N/A
Praxis Precision Medicines	$8.55M	932.79	-$303.27M	-$12.93	N/A

Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
Praxis Precision Medicines	N/A	-34.15%	-32.42%

Summary

Praxis Precision Medicines beats Lakefront Biotherapeutics American Depositary Shares on 8 of the 15 factors compared between the two stocks.

How does Lakefront Biotherapeutics American Depositary Shares compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

80.4% of Spyre Therapeutics shares are held by institutional investors. Comparatively, 32.5% of Lakefront Biotherapeutics American Depositary Shares shares are held by institutional investors. 15.7% of Spyre Therapeutics shares are held by company insiders. Comparatively, 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Lakefront Biotherapeutics American Depositary Shares, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	8,476.82	-$155.20M	-$1.95	N/A
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.56	$363.05M	-$1.41	N/A

Spyre Therapeutics currently has a consensus target price of $109.69, suggesting a potential upside of 27.86%. Lakefront Biotherapeutics American Depositary Shares has a consensus target price of $37.00, suggesting a potential upside of 23.99%. Given Spyre Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Spyre Therapeutics is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
Lakefront Biotherapeutics American Depositary Shares	0 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.56

Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-30.74%	-22.23%
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A

Spyre Therapeutics has a beta of 2.99, meaning that its stock price is 199% more volatile than the broader market. Comparatively, Lakefront Biotherapeutics American Depositary Shares has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market.

In the previous week, Lakefront Biotherapeutics American Depositary Shares had 9 more articles in the media than Spyre Therapeutics. MarketBeat recorded 11 mentions for Lakefront Biotherapeutics American Depositary Shares and 2 mentions for Spyre Therapeutics. Lakefront Biotherapeutics American Depositary Shares' average media sentiment score of 1.02 beat Spyre Therapeutics' score of 0.91 indicating that Lakefront Biotherapeutics American Depositary Shares is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lakefront Biotherapeutics American Depositary Shares	4 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Lakefront Biotherapeutics American Depositary Shares beats Spyre Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Lakefront Biotherapeutics American Depositary Shares compare to Ionis Pharmaceuticals?

Ionis Pharmaceuticals (NASDAQ:IONS) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

Ionis Pharmaceuticals has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market. Comparatively, Lakefront Biotherapeutics American Depositary Shares has a beta of 0.28, suggesting that its stock price is 72% less volatile than the broader market.

Ionis Pharmaceuticals presently has a consensus price target of $89.20, indicating a potential upside of 95.74%. Lakefront Biotherapeutics American Depositary Shares has a consensus price target of $37.00, indicating a potential upside of 23.99%. Given Ionis Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Ionis Pharmaceuticals is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ionis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.73
Lakefront Biotherapeutics American Depositary Shares	0 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.56

In the previous week, Ionis Pharmaceuticals had 6 more articles in the media than Lakefront Biotherapeutics American Depositary Shares. MarketBeat recorded 17 mentions for Ionis Pharmaceuticals and 11 mentions for Lakefront Biotherapeutics American Depositary Shares. Lakefront Biotherapeutics American Depositary Shares' average media sentiment score of 1.02 beat Ionis Pharmaceuticals' score of 0.39 indicating that Lakefront Biotherapeutics American Depositary Shares is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ionis Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lakefront Biotherapeutics American Depositary Shares	4 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Ionis Pharmaceuticals. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ionis Pharmaceuticals	$944M	8.02	-$381.39M	-$3.46	N/A
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.56	$363.05M	-$1.41	N/A

93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. Comparatively, 32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. 1.8% of Ionis Pharmaceuticals shares are owned by company insiders. Comparatively, 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to Ionis Pharmaceuticals' net margin of -64.76%. Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A

Summary

Lakefront Biotherapeutics American Depositary Shares beats Ionis Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Lakefront Biotherapeutics American Depositary Shares compare to Alkermes?

Alkermes (NASDAQ:ALKS) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends.

In the previous week, Alkermes had 10 more articles in the media than Lakefront Biotherapeutics American Depositary Shares. MarketBeat recorded 21 mentions for Alkermes and 11 mentions for Lakefront Biotherapeutics American Depositary Shares. Lakefront Biotherapeutics American Depositary Shares' average media sentiment score of 1.02 beat Alkermes' score of 0.67 indicating that Lakefront Biotherapeutics American Depositary Shares is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alkermes	5 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lakefront Biotherapeutics American Depositary Shares	4 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Alkermes has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market. Comparatively, Lakefront Biotherapeutics American Depositary Shares has a beta of 0.28, suggesting that its stock price is 72% less volatile than the broader market.

Lakefront Biotherapeutics American Depositary Shares has lower revenue, but higher earnings than Alkermes. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.48B	4.56	$241.66M	$0.38	105.66
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.56	$363.05M	-$1.41	N/A

95.2% of Alkermes shares are owned by institutional investors. Comparatively, 32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. 4.6% of Alkermes shares are owned by insiders. Comparatively, 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Alkermes has a net margin of 3.96% compared to Lakefront Biotherapeutics American Depositary Shares' net margin of 0.00%. Alkermes' return on equity of 4.15% beat Lakefront Biotherapeutics American Depositary Shares' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alkermes	3.96%	4.15%	2.19%
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A

Alkermes currently has a consensus target price of $54.47, indicating a potential upside of 35.67%. Lakefront Biotherapeutics American Depositary Shares has a consensus target price of $37.00, indicating a potential upside of 23.99%. Given Alkermes' stronger consensus rating and higher possible upside, equities research analysts clearly believe Alkermes is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	1 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.74
Lakefront Biotherapeutics American Depositary Shares	0 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.56

Summary

Alkermes beats Lakefront Biotherapeutics American Depositary Shares on 15 of the 17 factors compared between the two stocks.

Get Lakefront Biotherapeutics American Depositary Shares News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LKFT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LKFT vs. The Competition

Export

Metric	Lakefront Biotherapeutics American Depositary Shares	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.94B	$3.96B	$7.32B	$13.03B
Dividend Yield	N/A	3.64%	2.52%	14.03%
P/E Ratio	-21.16	13.94	275.05	25.61
Price / Sales	1.56	1,305.90	663.13	108.08
Price / Cash	40.46	40.88	28.02	35.00
Price / Book	0.63	15.41	10.53	6.44
Net Income	$363.05M	-$22.71M	$3.50B	$360.47M
7 Day Performance	0.84%	-3.19%	-1.73%	-1.03%
1 Month Performance	3.32%	-7.64%	-3.76%	-3.70%
1 Year Performance	-11.66%	28.11%	14.48%	3.62%

Lakefront Biotherapeutics American Depositary Shares Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LKFT Lakefront Biotherapeutics American Depositary Shares	2.5934 of 5 stars	$29.84 +1.6%	$37.00 +24.0%	-13.0%	$1.94B	$1.26B	N/A	1,310	Positive News
CYTK Cytokinetics	2.4418 of 5 stars	$65.27 -3.4%	$103.37 +58.4%	+28.3%	$8.13B	$88.04M	N/A	673	Analyst Upgrade Insider Trade
PRAX Praxis Precision Medicines	2.4941 of 5 stars	$287.69 -4.3%	$612.42 +112.9%	+435.4%	$8.03B	$8.55M	N/A	110
SYRE Spyre Therapeutics	2.4847 of 5 stars	$88.38 -3.9%	$109.69 +24.1%	+427.6%	$7.77B	$890K	N/A	112
IONS Ionis Pharmaceuticals	3.3954 of 5 stars	$43.49 -5.0%	$90.50 +108.1%	-30.6%	$7.24B	$944M	N/A	1,402

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LKFT) was last updated on 9/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lakefront Biotherapeutics American Depositary Shares (LKFT) Competitors

LKFT vs. CYTK, PRAX, SYRE, IONS, and ALKS

How does Lakefront Biotherapeutics American Depositary Shares compare to Cytokinetics?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Praxis Precision Medicines?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Spyre Therapeutics?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Ionis Pharmaceuticals?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Alkermes?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LKFT vs. The Competition

Lakefront Biotherapeutics American Depositary Shares Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lakefront Biotherapeutics American Depositary Shares (LKFT) Competitors

LKFT vs. CYTK, PRAX, SYRE, IONS, and ALKS

How does Lakefront Biotherapeutics American Depositary Shares compare to Cytokinetics?

Is CYTK or LKFT more profitable?

Which has more risk & volatility, CYTK or LKFT?

Do insiders & institutionals believe in CYTK or LKFT?

Does the media favor CYTK or LKFT?

Do analysts prefer CYTK or LKFT?

Which has preferable earnings & valuation, CYTK or LKFT?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Praxis Precision Medicines?

Do analysts rate LKFT or PRAX?

Which has more volatility & risk, LKFT or PRAX?

Do insiders and institutionals believe in LKFT or PRAX?

Does the media refer more to LKFT or PRAX?

Which has preferable valuation & earnings, LKFT or PRAX?

Is LKFT or PRAX more profitable?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Spyre Therapeutics?

Do institutionals & insiders believe in SYRE or LKFT?

Which has stronger earnings and valuation, SYRE or LKFT?

Do analysts rate SYRE or LKFT?

Is SYRE or LKFT more profitable?

Which has more volatility and risk, SYRE or LKFT?

Does the media prefer SYRE or LKFT?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Ionis Pharmaceuticals?

Which has more risk and volatility, IONS or LKFT?

Do analysts recommend IONS or LKFT?

Does the media favor IONS or LKFT?

Which has higher valuation & earnings, IONS or LKFT?

Do insiders & institutionals believe in IONS or LKFT?

Is IONS or LKFT more profitable?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Alkermes?

Does the media favor ALKS or LKFT?

Which has more volatility and risk, ALKS or LKFT?

Which has preferable valuation and earnings, ALKS or LKFT?

Do insiders and institutionals believe in ALKS or LKFT?

Is ALKS or LKFT more profitable?

Do analysts prefer ALKS or LKFT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LKFT vs. The Competition

Lakefront Biotherapeutics American Depositary Shares Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools